Mifepristona/uso terapêutico; Feminino; França; Humanos; Mifepristona/administração & dosagem; Mifepristona/farmacologia; Estados Unidos; United States Food and Drug Administration

Abortion Rate; Abortion, Induced; Americas; Anti-abortion Groups; Behavior; Biology; Bleeding; Breast Cancer; Cancer; Denmark; Developed Countries; Diseases; Endocrine System; Endometrial Effects; Endometrium; Europe; Family Planning; Fertility Control, Postconception; Fibroids; Finland; France; Genitalia; Genitalia, Female; Hormone Antagonists; Hormones; Hypertension; Interest Groups; Literature Review; Mediterranean Countries; Menstruation Disorders; Neoplasms; Neoplasms, Benign; Netherlands; North America; Northern America; Northern Europe; Norway; Ophthalmological Effects; Physiology; Political Factors; Premenstrual Tension; Prostaglandins; Prostaglandins, Synthetic; Ru-486--beneficial effects; Ru-486--side effects; Scandinavia; Signs And Symptoms; Smoking; Sweden; United Kingdom; United States; Urogenital System; Uterus; Vascular Diseases; Western Europe